Karenitecin

Summary

Karenitecin (CHEMBL1743260) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including ovarian cancer and melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 7
• Chemistry: 448.6 Da · C25H28N2O4Si

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743260
Name	Karenitecin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	54580717
Molecular formula	C25H28N2O4Si
Molecular weight	448.6
InChIKey	SYXGVIWFCCQOEK-VWLOTQADSA-N

SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O

IUPAC name: (19S)-19-ethyl-19-hydroxy-8-(2-trimethylsilylethyl)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione

Also known as: Karenitecin, KARENITECIN

Patent coverage: 6 distinct patent families (7 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ovarian cancer	3	MONDO:0008170	MONDO:0008170
melanoma	2	MONDO:0005105	EFO:0000756
brain neoplasm	2	MONDO:0021211	EFO:0003833
lung neoplasm	2	MONDO:0021117	MONDO:0008903
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00477282	PHASE3	COMPLETED	Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
NCT00010218	PHASE2	COMPLETED	Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
NCT00062478	PHASE2	COMPLETED	Study of Karenitecin (BNP1350) in Patients With Brain Tumors
NCT00062491	PHASE2	COMPLETED	Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
NCT00358319	PHASE1/PHASE2	TERMINATED	Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
NCT00014521	PHASE1	COMPLETED	Karenitecin in Treating Patients With Recurrent Malignant Glioma
NCT00097903	PHASE1	COMPLETED	Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).